

PHASE II TRIAL RESULTS ON ANTICANCER AGENT LENVIMA

According to the results of this study, lenvatinib plus everolimus showed superior PFS over everolimus alone which is recommended by the National Comprehensive Cancer Network (NCCN) guidelines as a 2nd-

Renal cell carcinoma is the most common form of cancer to affect the kidneys. The incidence of renal cell carcinoma in people aged in their late 50s is rising, and is more likely to affect men than women. The number of patients with renal cancer (including renal cell carcinoma and renal pelvic cancer) was estimated to be approximately 338,000 worldwide, including approximately 17,000 in Japan, 58,000 in the United States and 115,000 in Europe². While the standard treatment method primarily consists of surgery, once the cancer has metastasized or relapsed, the main treatment method becomes chemotherapy using molecular targeted drugs.

¹ Okamoto K, et al. Distinct Binding Mode of Multikinase Inhibitor Lenvatinib Revealed by Biochemical Characterization. *ACS Med. Chem. Lett.* 2015; 6, 89–94

² Globocan 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012 <http://globocan.iarc.fr/>